Avid Bioservices Inc (CDMO)

[JamesGMS]

Hutschi, Very informative Car-T review.

Thank you.

A Cure for Cancer? How CAR-T Therapy is Revolutionizing Oncology

https://labiotech.eu/car-t-therapy-cancer-review/

One of the most salient points the author makes can be found in the excerpt below:

Indeed, CAR-T cells have in fact been linked to severe side-effects, such as neurotoxicity and cytokine release syndrome. In 2016, several companies reported multiple deaths in late-stage clinical trials with CAR-T therapy. This made many realize that the technology might not be as perfect as they had originally expected.

These results mostly come from the most studied application of CAR-T cells, which targets the CD19 antigen found in B-cells. All the leading CAR-T companies target the CD19 antigen to treat B-cell malignancies, which include several forms of lymphoma and leukemia.

“The initial furor and excitement of CAR-T has led to extensive and rapid clinical development in the CD19 target space,” says David Gilham, R&D VP at Celyad. “Research is busy catching up at the moment, in particular concerning toxicity. The lack of good preclinical models hampers this work, but with clinical samples available, ongoing investigations are now closer to identifying the underlying mechanisms and further refining the approach.”

The above statement makes one wonder if the author is even aware of the work that is ongoing as MSK.

AACR’17 PPHM#2: 4-3-17/8am #1651 - Session: TUMOR MICROENVIRONMENT & CHECKPOINTS

“Targeting Phosphatidylserine in Combination with Adoptive T Cell Transfer Eliminates Advanced Tumors without Off-Target Toxicities in a Melanoma Preclinical Model” <=NEW(2nd) MSK STUDY

If the author truly is not aware he will be shortly.

Enjoy the football today.

James